FDA approves Imbruvica (ibrutinib) for MCL

Share this article:
J&J cancer med adds indication, lower dose
J&J cancer med adds indication, lower dose

The FDA approved Pharmacyclics/Janssen's mantle cell lymphoma drug Imbruvica Wednesday. This was one of the early drugs to receive the FDA's breakthrough therapy designation to help speed it through the review process.

Roche's Gazyva, approved last week, was the first breakthrough-status drug to get approved. It's indicated for chronic lymphocytic leukemia.

Johnson & Johnson estimates that the breakthrough label has shaved two years off development for ibrutinib, as noted by Reuters earlier this summer.

Imbruvica was also granted breakthrough therapy status for CL/small lymphocytic lymphoma with deletion of the short arm of chromosome 17 and Waldenstrom's macroglobulinemia.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.